neuromyelitis optica spectrum disorder with anti-AQP4 antibodies

Summary

neuromyelitis optica spectrum disorder with anti-AQP4 antibodies (MONDO:0035663) is a disease. A subtype of neuromyelitis optica — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	neuromyelitis optica spectrum disorder with anti-AQP4 antibodies
Mondo ID	MONDO:0035663
Orphanet	592850
ICD-11	73324466
UMLS	C5680295
MedGen	1842475
GARD	0022372
Is cancer (heuristic)	no

Also known as: Neuromyelitis optica spectrum disorder with anti-aquaporin 4 antibodies · NMOSD with anti-AQP4 antibodies

Disease family

This is a subtype of neuromyelitis optica. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › neuromyelitis optica › neuromyelitis optica spectrum disorder with anti-AQP4 antibodies

Related subtypes (2): neuromyelitis optica spectrum disorder with anti-MOG antibodies, neuromyelitis optica spectrum disorder without anti-MOG and without anti-AQP4 antibodies

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.